The Accounts Companies House intelligence

VERNALIS (R&D) LIMITED

#01985479 · Active · Incorporated 1986-02-04 (40y 3m) · Last filing 2025-10-03 (7mo ago)
Health Care · SIC 72110 · M Professional, Scientific & Technical Activities · Full accounts

Get an alert when VERNALIS (R&D) LIMITED files next

Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.

Free · confirmation link first · unsubscribe in one click

Next accounts due

2026-09-30 (in 4mo)

Last filed for 2024-12-31

Confirmation statement due

2026-10-14 (in 5mo)

Last made up 2025-09-30

Watchouts

None on the register

Cash

£5M

Latest balance sheet

Net assets

£2M

Equity attributable

Employees

73

-8.8% vs 2023

Profit before tax

£849K

+127.6% vs 2023

Name history

Renamed 7 times since incorporation

  1. VERNALIS (R&D) LIMITED 2003-12-18 → present
  2. VERNALIS (OXFORD) LIMITED 2003-10-01 → 2003-12-18
  3. BRITISH BIOTECH PHARMACEUTICALS LIMITED 1994-07-29 → 2003-10-01
  4. BRITISH BIO-TECHNOLOGY LIMITED 1994-06-03 → 1994-07-29
  5. BRITISH BIO-TECHNOLOGY LIMITED 1988-07-15 → 1994-06-03
  6. BRITISH BIOTECHNOLOGY LIMITED 1986-08-18 → 1988-07-15
  7. BIOTECHNOLOGY (UK) LIMITED 1986-04-04 → 1986-08-18
  8. GROWTRIM LIMITED 1986-02-04 → 1986-04-04

Accounts

2-year trend · latest reflected 2024-12-31

Metric Trend 2023-12-312024-12-31
Turnover £10,056,000£12,811,000
Operating profit -£2,604,000£1,380,000
Profit before tax -£3,074,000£849,000
Net profit -£2,065,000£201,000
Cash —£4,840,000
Total assets less current liabilities ——
Net assets —£2,217,000
Equity —£2,217,000
Average employees 8073
Wages £5,351,000£5,077,000

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Ratios

Computed from the line items above — sparklines read oldest → newest

Ratio Trend 2023-12-312024-12-31
Operating margin -25.9%10.8%
Net margin -20.5%1.6%
Gearing (liabilities / total assets) —84.3%
Current ratio —0.79x
Interest cover -5.54x2.60x

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Audit & accounting basis

Accounting basis
FRS 101
Reporting scope
Standalone (parent only)
Auditor
Grant Thornton UK LLP
Audit opinion
Unqualified (clean)
Going concern
Affirmed

“dependent on the continuing financial support from its ultimate parent company, HitGen Inc. HitGen Inc. had adequate cash reserves at 31 December 2024 (£35.6 million) to support the Company. After making enquires, the Directors have a reasonable expectation that the Company has adequate resources to continue in operation for the foreseeable future.”

Group structure

  1. VERNALIS (R&D) LIMITED · parent
    1. Dania Therapeutics ApS 32.4% · Denmark · research services

Significant events

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

People

3 active · 40 resigned

Name Role Appointed Born Nationality
WALLCRAFT, Susan Jean Secretary 2020-12-02 — —
LI, Jin, Dr Director 2020-12-02 Feb 1963 British
LI, Michael Director 2020-12-02 May 1996 British
Show 40 resigned officers
Name Role Appointed Resigned
BERKMAN, Charles Stuart Secretary 2019-04-01 2020-12-02
BOND, Jonathan Charles Howard Secretary 2001-01-26 2004-06-30
HOOD, Alison Mary Secretary 2009-09-30 2010-11-30
ILETT, John Edward Secretary 1999-08-02 2000-08-18
KISSANE, Kevin Patrick Secretary 2010-11-30 2017-11-01
MACKNEY, David Secretary 2017-11-01 2018-01-25
SLATER, John Andrew Duncan Secretary 2004-10-29 2009-09-30
WALLCRAFT, Susan Jean Secretary 2018-01-25 2019-03-31
WEIR, Anthony John Secretary — 2001-01-26
WORRALL, Peter Brian Secretary 2004-06-30 2004-10-29
BERKMAN, Charles Stuart Director 2018-10-12 2020-12-02
DOVEY, Brian Hugh Director — 1993-03-23
DRUMMOND, Alan Hastings Director 1994-05-26 2000-03-17
EDWARDS, Timothy Peter Warren Director 2001-08-03 2003-09-10
FALLEN, Malcolm James Director 1997-10-01 1999-03-31
FELLNER, Peter John, Dr Director 2008-11-14 2014-12-18
FOEHR, Matthew William Director 2018-10-12 2020-12-02
GARLAND, Ian Director 2009-06-15 2018-10-12
GOLDSTEIN, Elliot Paul, Dr Director 1998-09-24 2002-11-04
GORDON, John Laurie, Dr Director — 1994-06-24
GRAY, Stephen Marius Director — 1993-03-23
HUTCHISON, John Blundell, Dr Director 2004-10-01 2007-08-31
IRWIN, Thomas Ronald Director 1993-03-23 1996-09-30
JACK, David, Sir Director — 1993-03-23
JENSEN, Peder Klosterskov, Doctor Director 1998-01-26 1999-07-31
KIRBY, Pamela Josephine, Dr Director 1996-09-02 1998-09-30
KORENBERG, Matthew Edward Director 2018-10-12 2020-12-02
LEATHERS, David Frederick James Director — 1993-03-23
LEWIS, Peter John, Dr Director 1992-07-09 1997-06-30
MACKNEY, David Director 2009-06-15 2018-10-12
MCCULLAGH, Keith Graham, Dr Director — 1998-09-23
MOLONEY, Brian Director 2022-11-07 2024-10-04
NOBLE, James Julian Director — 1997-02-12
REECE, Charles Hugh, Sir Director — 1993-03-23
RICHARDS, Brian Mansel, Sir Director — 1993-03-23
SLATER, John Andrew Duncan Director 2008-04-20 2009-09-30
STURGE, Simon Director 2003-04-23 2008-02-29
WEIR, Anthony John Director 1999-03-31 2008-11-14
WEIR, Anthony John Director 1997-02-12 1997-10-01
WOOD, Lars Michael Director 2020-12-02 2023-08-14

Ownership

Persons with significant control

Name Kind Nature of control Notified Status
Hitgen Uk Ltd Corporate entity Shares 75–100%, Voting 75–100%, Appoints directors 2020-12-02 Active
Vernalis Plc Corporate entity Shares 75–100%, Voting 75–100%, Appoints directors 2016-04-06 Ceased 2020-12-02

Filing timeline

Last 20 of 250 total filings

Date Type Category Description
2025-10-03 CS01 confirmation-statement Confirmation statement with no updates PDF
2025-06-13 AA accounts Accounts with accounts type full
2024-10-08 CS01 confirmation-statement Confirmation statement with no updates PDF
2024-10-04 TM01 officers Termination director company with name termination date PDF
2024-07-18 AA accounts Accounts with accounts type full
2023-10-16 CS01 confirmation-statement Confirmation statement with no updates PDF
2023-08-30 TM01 officers Termination director company with name termination date PDF
2023-07-24 AA accounts Accounts with accounts type full
2022-11-07 AP01 officers Appoint person director company with name date PDF
2022-09-30 CS01 confirmation-statement Confirmation statement with updates PDF
2022-07-01 AA accounts Accounts with accounts type full
2021-10-01 CS01 confirmation-statement Confirmation statement with updates PDF
2021-07-22 AA accounts Accounts with accounts type full
2020-12-04 AP03 officers Appoint person secretary company with name date PDF
2020-12-02 PSC02 persons-with-significant-control Notification of a person with significant control PDF
2020-12-02 PSC07 persons-with-significant-control Cessation of a person with significant control PDF
2020-12-02 AP01 officers Appoint person director company with name date PDF
2020-12-02 AP01 officers Appoint person director company with name date PDF
2020-12-02 AP01 officers Appoint person director company with name date PDF
2020-12-02 TM01 officers Termination director company with name termination date PDF

Public-record activity

Raw counts from Companies House — last 12–24 months

Filings
2

last 12 months

Capital events
0

last 24 months

Officers appointed
0

last 12 months

Officers resigned
0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

Year-on-year

FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Official Companies House page